Citations 1
First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-posi
Piccart, Martine , Holmes, Andrew , Baselga, José , Viale, Giuseppe , Zujewski, Jo Anne , Goldhirsch, Aron, Jackisch, Christian , Láng, István, Smith, Ian E., Boyle, Frances , Gelber, Richard D. , Perez, Edith A. , Azambuja, Evandro de , Dueck, Amylou C. , Zujewski, Jo Anne , Santillana, Sergio, Pritchard, Kathleen I. , Wolff, Antonio C. , Untch, Michael , Xu, Binghe , Gómez, Henry
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: LBA4-LBA4
